Los Angeles California (PRWEB) November 07 2013 A new randomized clinical trial (RCT) published in the November 1 2013 issue of the journal Spine (1) provides new evidence for the efficacy of etanercept used off-label for relief of persistent sciatica associated with lumbar disc herniation a common health problem with significant unmet medical need. Etanerc

A new randomized clinical trial (RCT) published in the November 1, 2013 issue of the journal Spine (1) provides new evidence for the efficacy of etanercept used off-label for relief of persistent sciatica associated with lumbar disc herniation, a common health problem with significant unmet medical need. Etanercept belongs to the class of potent anti-inflammatory drugs known as TNF inhibitors.

The new etanercept study follows a 2012 comparative effectiveness trial of epidural etanercept versus an epidural steroid injection that found etanercept to be superior to the epidural steroid(cortisone) injection(2).

The new Spine study joins three previous RCTs as the fourth RCT supporting the efficacy of etanercept for treating disc-related pain(1-4). The clinical evidence of the effectiveness of etanercept for this indication has been accumulating for more than a decade(1-9). Increasing basic science and clinical evidence supports the scientific rationale of TNF inhibition for neuroinflammation(10-19).

The first account of the favorable clinical effect of etanercept for sciatica, and the invention of epidural administration of etanercept for this indication, was published in 2001, authored by Edward Tobinick, M.D., the founder of the Institute of Neurological Recovery(INR)(20). Dr. Tobinick and his colleagues have written multiple peer-reviewed articles documenting the clinical effects of perispinal etanercept used at the INR off-label for sciatica, cervical radiculopathy, intractable low back pain and related symptoms associated with lumbar disc herniation(5-9, 21). Perispinal administration of etanercept is a patented invention of Dr. Tobinick(21). Please note that results can vary, not all patients respond, etanercept may have adverse effects and is off-label for neurological indications.

Etanercept holds great promise for the large patient population with intractable spinal pain for which existing medical treatment options have not provided adequate pain relief.

(Date:8/15/2017)... ... 15, 2017 , ... Nanomedical Diagnostics , a cutting-edge ... the launch of the new NHS Agile biosensor chip . The new ... a wide range of molecules, including small and large molecules, peptides, proteins, and ...

(Date:8/15/2017)... ... August 15, 2017 , ... Coffea arabica ... biotic and abiotic factors. During this educational webinar, participants will learn about the ... as gain a better understanding of how genomics is important for coffee breeding ...

(Date:8/10/2017)... Philadelphia, PA (PRWEB) , ... August 09, 2017 ... ... back to the classroom next week-- as students. From August 14th through the ... Institute. The institute, which debuted in the summer of 2016, provides Philadelphia-based middle ...

(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...

(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...